Drug Profile
Research programme: multiple myeloma therapy - Prolexys
Alternative Names: PRLX nextgenLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Prolexys Pharmaceuticals
- Class Small molecules
- Mechanism of Action Genetic transcription modulators; Ras gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (PO)
- 11 Dec 2007 Preclinical trials in Multiple myeloma in USA (PO)